Research finds JAK inhibitors weaken antiviral defenses, facilitating virus spread in human cells — Evidence Review
Published in NAR Molecular Medicine, by researchers from Norwegian University of Science and Technology (NTNU)
Researched by
— the AI search engine for science
Table of Contents
Scientists at the Norwegian University of Science and Technology have found that certain anti-inflammatory drugs, specifically JAK inhibitors, may reduce the body’s antiviral defenses and help viruses spread more easily—a concern that is both supported and complicated by prior research. While related studies confirm that JAK inhibitors can impair immune pathways and increase some viral infection risks, others highlight potential antiviral uses or benefits in severe COVID-19, showing the relationship between these drugs and viral infections is complex (1, 3, 4).
- Selective JAK inhibitors, such as TYK2 inhibitors, may preserve some antiviral immune responses (e.g., interferon lambda-mediated), whereas broader JAK1/2 inhibitors like baricitinib can suppress both protective and inflammatory pathways, as shown in in vitro and animal studies (1).
- Meta-analyses of JAK inhibitors in hospitalized COVID-19 patients suggest that, despite immunosuppressive effects, these drugs can reduce mortality and serious adverse events, but may not significantly increase secondary infection rates, indicating a context-dependent risk-benefit profile (3, 12, 13).
- Reviews consistently report an increased risk of certain viral infections, especially herpes zoster, with JAK inhibitor use in inflammatory diseases, underlining the need for careful patient monitoring when these drugs are prescribed (4).
Study Overview and Key Findings
The recent study addresses an important gap in understanding the safety profile of JAK inhibitors—drugs widely used to treat autoimmune and inflammatory diseases such as rheumatoid arthritis. The research gains relevance in the context of ongoing viral outbreaks and the expanding clinical use of JAK inhibitors. By highlighting a potential mechanism for increased viral susceptibility, the findings bring new attention to the balance between immunosuppression and infection risk in treatment decisions, particularly during epidemic situations.
| Property | Value |
|---|---|
| Organization | Norwegian University of Science and Technology (NTNU) |
| Journal Name | NAR Molecular Medicine |
| Authors | Denis Kainov, Erlend Ravlo, Aleksandr Ianevski |
| Population | Cells from lungs, eyes, and brain |
| Methods | In Vitro Study |
| Outcome | Impact of JAK inhibitors on antiviral defenses |
| Results | JAK inhibitors weaken antiviral protection, aiding virus spread. |
Literature Review: Related Studies
To place these findings in context, we searched the Consensus paper database, which contains over 200 million research papers. The following specific search queries were used to identify relevant studies:
- JAK inhibitors antiviral protection effects
- virus spread mechanisms common drugs
- antiviral treatment outcomes JAK inhibitors
Related Studies Table
| Topic | Key Findings |
|---|---|
| How do JAK inhibitors impact host antiviral defenses and infection risk? | - Broad JAK inhibitors can suppress interferon-mediated antiviral responses and increase susceptibility to viral infections, including herpes zoster (1, 4). - Selective TYK2 inhibition may preserve certain antiviral pathways, suggesting not all JAK inhibitors have equal impact on infection risk (1). |
| Are JAK inhibitors beneficial or harmful in the context of viral infections such as COVID-19? | - Meta-analyses show JAK inhibitors reduce mortality and serious adverse events in hospitalized COVID-19 patients, without significantly increasing secondary infections (3, 12, 13). - Ruxolitinib and baricitinib demonstrated potential antiviral and anti-inflammatory benefits in severe COVID-19 cases (11, 12, 13). |
| Can JAK inhibitors or related compounds be repurposed as antiviral agents? | - Some JAK inhibitors (and natural compounds like gingerenone A) exhibit direct antiviral activity against viruses such as influenza A in vitro and in animal models (2, 5). - The JAK-STAT pathway is a target for pan-viral therapeutic strategies, though safety and specificity remain concerns (5). |
| What are the broader challenges and strategies in targeting host factors to prevent viral spread? | - Targeting host pathways, including JAK-STAT, can offer broad-spectrum antiviral effects but increases the risk of cellular side effects and impaired immune responses (7). - Mechanisms such as tunneling nanotubes also facilitate viral spread, underscoring the complexity of host-virus interactions (8, 9). |
How do JAK inhibitors impact host antiviral defenses and infection risk?
The new study’s finding that JAK inhibitors weaken antiviral defenses aligns with prior research indicating that these drugs can suppress critical immune pathways, making users more susceptible to viral infections. However, the degree of immunosuppression varies by the specificity of the inhibitor: broader JAK1/2 inhibitors are more likely to blunt both protective and inflammatory responses, while selective inhibitors may offer a better safety profile.
- Broad-spectrum JAK inhibitors, such as baricitinib, reduce the activity of genes involved in interferon-mediated antiviral protection, increasing infection risk (1, 4).
- Selective TYK2 inhibition may avoid some of these issues, preserving interferon-lambda responses and reducing the risk of viral infections (1).
- Clinical experience has documented increased herpes zoster reactivation with JAK inhibitor therapy, especially among immunocompromised patients (4).
- The new NTNU study adds mechanistic evidence using human tissue models to demonstrate that JAK inhibitors facilitate viral spread in various cell types.
Are JAK inhibitors beneficial or harmful in the context of viral infections such as COVID-19?
While JAK inhibitors suppress antiviral immunity, clinical trials and meta-analyses in COVID-19 suggest these drugs can reduce mortality and severe complications in hospitalized patients, likely by dampening harmful inflammation (“cytokine storms”). However, their impact on infection risk appears modest in these settings, perhaps due to the acute and controlled use.
- Meta-analyses report a reduction in all-cause mortality and serious adverse events in hospitalized COVID-19 patients treated with JAK inhibitors, with little to no increase in secondary infections (3, 12, 13).
- Randomized trials with ruxolitinib and baricitinib demonstrated improved clinical and radiological outcomes in severe COVID-19, balanced against their immunosuppressive effects (11, 12).
- The timing, dosage, and patient population are critical in determining whether JAK inhibitors’ benefits outweigh potential infection risks (12).
- The new study underscores the need for caution, especially when prescribing JAK inhibitors outside acute hospital settings or during outbreaks of other viruses.
Can JAK inhibitors or related compounds be repurposed as antiviral agents?
Some research points to the potential for JAK inhibitors or related compounds to act directly as antivirals, targeting host pathways essential for viral replication. This dual role—as both immunomodulators and potential antivirals—highlights the need for careful selection and monitoring of these agents.
- Natural compounds like gingerenone A, which inhibit JAK2, have shown antiviral effects against influenza A in vitro and in animal studies (2).
- The JAK-STAT pathway is a promising target for broad antiviral therapies, but balancing efficacy and immune suppression is crucial (5).
- Not all JAK inhibitors have the same spectrum or potency of antiviral activity, and their effects are context-dependent (1, 2, 5).
- The findings from the NTNU study suggest that, while some JAK inhibitors may have antiviral potential, their immunosuppressive effects could inadvertently facilitate viral spread under certain conditions.
What are the broader challenges and strategies in targeting host factors to prevent viral spread?
Targeting host pathways, such as JAK-STAT, for antiviral therapy offers theoretical advantages—including broad-spectrum activity and a higher barrier to viral resistance. However, interfering with host defenses can have unintended consequences, such as increased susceptibility to infection or cellular toxicity.
- Host-directed antivirals can provide broad protection but raise concerns about off-target effects and immune compromise (7).
- Mechanisms like tunneling nanotubes enable viruses to spread even in the presence of antiviral drugs, complicating therapeutic strategies (8).
- Computational models of host-virus dynamics are increasingly used to optimize therapy and predict adverse outcomes (9).
- The NTNU study’s use of organoid models and gene expression analysis provides a platform for further research into host-pathogen interactions and drug safety.
Future Research Questions
Although the new findings provide valuable insights into the risks associated with JAK inhibitor therapy, several important questions remain. Further research is needed to clarify the clinical significance, compare different JAK inhibitor classes, and develop strategies to mitigate infection risk while preserving therapeutic benefits.
| Research Question | Relevance |
|---|---|
| How do different JAK inhibitor classes (TYK2 vs JAK1/2) differ in their impact on antiviral immune responses? | Understanding distinctions between selective and broad JAK inhibitors could inform safer prescribing practices and guide therapy selection to minimize infection risk (1, 4). |
| What is the clinical risk of viral reactivation or new infection in patients on JAK inhibitors during viral outbreaks? | Quantifying infection risks in real-world settings, including during pandemics, is crucial for patient safety and public health planning (3, 4, 12). |
| Can JAK inhibitors be safely used as antiviral agents without compromising host defenses? | Investigating the feasibility of using JAK inhibitors as direct antivirals requires understanding their immunosuppressive thresholds and the balance between efficacy and safety (2, 5, 7). |
| How can host-directed antiviral therapies be optimized to limit viral spread without increasing susceptibility to other infections? | Optimizing host-targeted therapies involves fine-tuning drug specificity, dose, and timing to achieve antiviral benefits while minimizing adverse effects (7, 9). |
| What are the mechanisms by which JAK inhibitors facilitate cell-to-cell virus spread in different tissues? | Elucidating tissue-specific mechanisms of viral dissemination under JAK inhibition could help identify at-risk populations and inform targeted interventions (8, 9). |
This article provides an overview of recent findings that JAK inhibitors may compromise antiviral defenses and facilitate virus spread, placing these results in the context of existing research and highlighting critical questions for future investigation.